SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain

04 مايو 2023 09:00:01 بحسب Nasdaq GlobeNewswire

Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023

28 أبريل 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento’s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend

25 أبريل 2023 19:30:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa Region

17 أبريل 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders

14 أبريل 2023 18:32:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders

05 أبريل 2023 17:27:43 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

27 مارس 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

21 مارس 2023 09:00:02 بحسب Nasdaq GlobeNewswire

Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

08 مارس 2023 10:13:07 بحسب Nasdaq GlobeNewswire

Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

27 فبراير 2023 09:00:01 بحسب Nasdaq GlobeNewswire